Thiazolo-pyridopyrimidines: An in silico evaluation as a lead for CDK4/6 inhibition, synthesis and cytotoxicity screening against breast cancer cell lines

Chaithra R Shetty ¹ , C. S. Shastry ² * , Parasuraman P ³, Srinivas Hebbar ⁴

Cited by CrossRef: 1

1- Addoum B, Chebaibi M, Baammi S, Achour I, Drissi H, Bourhia M, chaoui I, El Mzibri M, Attaleb M, Dakir M, Elmakssoudi A, Benbacer L. Network pharmacology, molecular docking, and dynamics simulation of 7-phenyl-5-(p-tolyl)pyrido[2,3-d] pyrimidine-4-amine as anticancer agents with multitarget inhibitory action. Computers in Biology and Medicine. 2026;213:111785 [Crossref]

2- Dinesh B, Bandral S, Sadashivappa N, Ganjipete S, Ammunje D, Kunjiappan S, Theivendren P, Jays J, Pavadai P. Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy. CPD. 2025;31(31):2481 [Crossref]

3- Alamshany Z, Tashkandi N, Othman I, Anwar M, Nossier E. Development of benzothiazole-grafted heterocyclic ring systems as new antiproliferative hybrids inducing cell cycle arrest and apoptosis in triple-negative breast cancer. Journal of Molecular Structure. 2026;1371:146476 [Crossref]

4- Avdičević A, Lešnik S, Bren U, Čavka L. CDK4/6 Inhibitors for Breast Cancer Therapy—A Review of Clinical Trials, Structural and Computational Approaches. Pharmaceuticals. 2026;19(4):610 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate (2024): 19%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar; SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of
Follower of ICMJE
Permission: Creative Commons